Bellicum Pharmaceuticals, Inc. (BLCM) saw its loss widen to $21.97 million, or $0.80 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $15.08 million, or $0.56 a share.
Revenue during the quarter surged 39.13 percent to $0.13 million from $0.09 million in the previous year period.
Operating loss for the quarter was $21.45 million, compared with an operating loss of $15.18 million in the previous year period.
"We had a productive first quarter across our pipeline," said Rick Fair, Bellicum's president & chief executive officer. "We continued to make progress on the registration trial for BPX-501, and presented updated clinical data highlighting its potential to transform patients’ lives. We are actively recruiting initial clinical trials with our controllable CAR T and TCR product candidates, and presented preclinical data on exciting new enhancements to our pioneering technology platform. This progress underscores our commitment to developing novel cell therapies in areas of dire need."
Working capital increases sharply
Bellicum Pharmaceuticals, Inc. has recorded an increase in the working capital over the last year. It stood at $136.81 million as at Mar. 31, 2017, up 32.19 percent or $33.32 million from $103.50 million on Mar. 31, 2016. Current ratio was at 11.15 as on Mar. 31, 2017, down from 14.98 on Mar. 31, 2016.
Days sales outstanding went down to 155 days for the quarter compared with 218 days for the same period last year.
Debt increases substantially
Bellicum Pharmaceuticals, Inc. has witnessed an increase in total debt over the last one year. It stood at $30.31 million as on Mar. 31, 2017, up 102.40 percent or $15.34 million from $14.98 million on Mar. 31, 2016. Total debt was 16.06 percent of total assets as on Mar. 31, 2017, compared with 9.16 percent on Mar. 31, 2016. Debt to equity ratio was at 0.21 as on Mar. 31, 2017, up from 0.11 as on Mar. 31, 2016.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
